These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 6713889)

  • 1. Dialysis fluids as a source of aluminum accumulation.
    Savory J; Wills MR
    Contrib Nephrol; 1984; 38():12-23. PubMed ID: 6713889
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlation of serum aluminum values with tissue aluminum concentration.
    De Broe ME; Van de Vyver FL; Bekaert AB; D'Haese P; Paulus GJ; Visser WJ; Van Grieken R; de Wolff FA; Verbueken AH
    Contrib Nephrol; 1984; 38():37-46. PubMed ID: 6713899
    [No Abstract]   [Full Text] [Related]  

  • 3. Aluminum osteopathy.
    Cournot-Witmer G
    Contrib Nephrol; 1984; 38():59-64. PubMed ID: 6713901
    [No Abstract]   [Full Text] [Related]  

  • 4. Gastrointestinal absorption of aluminium in chronic renal insufficiency.
    Knoll O; Kellinghaus H; Bertram HP; Zumkley H; Graefe U
    Contrib Nephrol; 1984; 38():24-31. PubMed ID: 6713897
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness of deferiprone (L1) releasing the aluminum bound to plasma proteins in chronic renal failure.
    Canteros-Piccotto MA; Fernández-Martín JL; Cannata-Ortiz MJ; Cannata-Andía JB
    Nephrol Dial Transplant; 1996 Jul; 11(7):1488-9. PubMed ID: 8815427
    [No Abstract]   [Full Text] [Related]  

  • 6. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
    Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Red blood cell aluminum in patients with renal failure and effect of desferrioxamine infusion.
    Umeda M; Tsurusaki K; Kamikawa S; Izumi N; Yasumoto R; Kishimoto T; Maekawa M
    Blood Purif; 1990; 8(5):295-300. PubMed ID: 2091689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylaxis and methods for early recognition of aluminium intoxication.
    Fuchs C; Armstrong VW; Quellhorst E; Scheler F
    Contrib Nephrol; 1984; 38():81-94. PubMed ID: 6713903
    [No Abstract]   [Full Text] [Related]  

  • 9. Frequency of elevated serum aluminum levels in adult dialysis patients.
    Jaffe JA; Liftman C; Glickman JD
    Am J Kidney Dis; 2005 Aug; 46(2):316-9. PubMed ID: 16112051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum binding of aluminum.
    King SW; Wills MR; Savory J
    Res Commun Chem Pathol Pharmacol; 1979 Oct; 26(1):161-9. PubMed ID: 515501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of magnesium and zinc levels in blood in end stage renal disease patients treated by hemodialysis or peritoneal dialysis.
    Pietrzak I; Bladek K; Bulikowski W
    Magnes Res; 2002 Dec; 15(3-4):229-36. PubMed ID: 12635877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperaluminaemia from aluminum resins in renal failure.
    Berlyne GM; Ben-Ari J; Pest D; Weinberger J; Stern M; Levine R; Gilmore GR
    Lancet; 1970 Sep; 2(7671):494-6. PubMed ID: 4194940
    [No Abstract]   [Full Text] [Related]  

  • 13. Reduced in vitro binding of tryptophan by plasma in uremia.
    de Torrente A; Glazer GB; Gulyassy P
    Kidney Int; 1974 Oct; 6(4):222-9. PubMed ID: 4427418
    [No Abstract]   [Full Text] [Related]  

  • 14. The dialysis dementia syndrome and aluminum intoxication.
    Sideman S; Manor D
    Nephron; 1982; 31(1):1-10. PubMed ID: 7110469
    [No Abstract]   [Full Text] [Related]  

  • 15. [Serum aluminum concentration and the deferoxamine test in a group of patients under chronic hemodialysis].
    de Sousa FT; Barbas JM; dos Santos JP; Mil-Homens MC; Aniceto JP; Melo JA; Rosário EM; Fonseca AP; Vizela MH
    Acta Med Port; 1986; 7(4):161-4. PubMed ID: 3825604
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipofuscin products, lipid peroxides and aluminum accumulation in red blood cells of hemodialyzed patients.
    Jain SK; Abreo K; Duett J; Sella ML
    Am J Nephrol; 1995; 15(4):306-11. PubMed ID: 7573188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aluminum binding to organic acids and plasma proteins. Implications for dialysis encephalopathy.
    Trapp GA
    J Environ Pathol Toxicol Oncol; 1985; 6(1):15-20. PubMed ID: 4067831
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapy of aluminium overload (II).
    Ackrill P; Day JP
    Contrib Nephrol; 1984; 38():78-80. PubMed ID: 6713902
    [No Abstract]   [Full Text] [Related]  

  • 19. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure.
    Olsen GD; Bennett WM; Porter GA
    Clin Pharmacol Ther; 1975 Jun; 17(6):677-84. PubMed ID: 1095281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the value of plasma/serum aluminum in patients with chronic renal failure?
    Winney RJ; Cowie JF; Robson JS
    Clin Nephrol; 1985; 24 Suppl 1():S2-8. PubMed ID: 3842104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.